CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Globe Newswire•10/08/2026•07:30 ET
0
Whiz Insights
Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB)
Neflamapimod awarded Innovation Passport Designation under the United Kingdom’s Innovative Licensing and Access Pathway (ILAP) for development in DLB
Get started
Create a free account to read the full story.